Cell protective methods and compositions
AssigneeThe University of North Carolina at Chapel Hill
InventorsJian Liu, Jine Li, Guowei Su, Rafal Pawlinski, Erica Sparkenbaugh
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe University of North Carolina at Chapel Hill
InventorsJian Liu, Jine Li, Guowei Su, Rafal Pawlinski, Erica Sparkenbaugh
Estimating the term…
Chondroitin sulfate compounds comprising chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, C8 backbone 13 mer, C8-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof are provided. Methods of treating histone toxicity in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the histone toxicity in the subject. Pharmaceutical compositions for use in treating histone toxicity and/or sepsis are provided. Methods of treating sepsis in a subject are provided, the methods including administering to a subject a chondroitin sulfate compound to treat the sepsis in the subject.
A method of treating histone toxicity in a subject, the method comprising:
The method of any of the above claims, wherein the chondroitin sulfate compound comprises a CS backbone, CS-A, CS-E, CS-C and/or combinations thereof.
The method of any of the above claims, wherein the chondroitin sulfate compound comprises chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, CS backbone 13 mer, CS-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof.
The method of any of the above claims, wherein the chondroitin sulfate compound comprises one or more of the following structures:
The method of any of the above claims, wherein the chondroitin sulfate compound is administered as part of a pharmaceutical composition.
The method of any of the above claims, wherein the pharmaceutical composition comprises a CS compound and a pharmaceutically acceptable carrier or adjuvant for administration of the CS.
A pharmaceutical composition for use in treating histone toxicity and/or sepsis, the composition comprising one or more chondroitin sulfate compounds and a pharmaceutically acceptable carrier.
A method of treating sepsis in a subject, the method comprising:
The method of any of the above claims, wherein the chondroitin sulfate compound comprises a CS backbone, CS-A, CS-E, CS-C and/or combinations thereof.
The method of any of the above claims, wherein the chondroitin sulfate compound comprises chondroitin sulfate backbone 19 mer, CS-A 19 mer, CS-C 19 mer, CS-E 19 mer, CS backbone 13 mer, CS-A 13 mer, CS-C 13 mer, CS-E 13 mer and/or combinations thereof.
The method of any of the above claims, wherein the chondroitin sulfate compound comprises one or more of the following structures:
The method of any of the above claims, wherein the chondroitin sulfate compound is administered as part of a pharmaceutical composition.
The method of any of the above claims, wherein the pharmaceutical composition comprises a CS compound and a pharmaceutically acceptable carrier or adjuvant for administration of the CS.
Dependencies are inferred from the claim text.